Streetbeat News

Products Services

TMO

The FDA has approved Thermo Fisher Scientific's blood test for preeclampsia, a pregnancy-related illness. The test is the first blood-based biomarker immunoassay to receive breakthrough designation and clearance for risk assessment and clinical management of preeclampsia.

Portfolio Pulse from Vandana Singh

May 19, 2023 | 1:00 pm

SHIBUSD

Swiss-based crypto wallet company Tangem is developing card-shaped cold wallets specifically for Shiba Inu (CRYPTO: SHIB) meme coin. Pre-orders will be available from May 29. The SHIB Wallet will support over 6,000 cryptocurrencies and various DeFi applications. Following the news, SHIB burn rate spiked by 182%.

Portfolio Pulse from Mehab Qureshi

May 19, 2023 | 12:53 pm

QABSY

Qantas Airways plans to expand its international network with more aircraft and new routes amid solid travel demand and aviation industry recovery. The company will add around one million seats to its international network starting late October and aims to reach 100% of pre-covid capacity by March 2024. Qantas will lease two Airbus A330 aircraft from Finnair and introduce more flights to destinations like Tokyo, Los Angeles, and New York.

Portfolio Pulse from Nabaparna Bhattacharya

May 19, 2023 | 12:51 pm

AZYO

Aziyo Biologics (AZYO) shares are trading higher after the company announced it will present clinical data from the HEAL Study at HRS 2023 on May 21st.

Portfolio Pulse from Benzinga Newsdesk

May 19, 2023 | 12:46 pm

ABT

STXS

Stereotaxis (NYSE:STXS) and Abbott (NYSE:ABT) announced a global collaboration to integrate Abbott's EnSite™ X EP System with Stereotaxis' Robotic Magnetic Navigation systems. The integrated technologies are cleared for use in Europe, with additional regulatory clearances expected in the coming months.

Portfolio Pulse from Happy Mohamed

May 19, 2023 | 12:40 pm

CTLT

Catalent executive stated that their customer supply situation remains healthy and they can sufficiently service the demand. They expect the combination of COVID and other mRNA respiratory vaccines to remain a meaningful part of their revenue stream in the coming years.

Portfolio Pulse from Happy Mohamed

May 19, 2023 | 12:35 pm

NBIX

Neurocrine Biosciences has announced the publication of full Kinect-HD Phase 3 study results of Valbenazine for the treatment of chorea associated with Huntington's disease in The Lancet Neurology.

Portfolio Pulse from Benzinga Newsdesk

May 19, 2023 | 12:33 pm

MNMD

MindMed's Phase 2b clinical trial on LSD compound MM-120 for Generalized Anxiety Disorder (GAD) treatment has enrolled and dosed over 50% of its participants. The company expects to announce topline results of the study in late 2023.

Portfolio Pulse from Lara Goldstein

May 19, 2023 | 12:31 pm

MRNA

Moderna reports positive interim data from the Phase 1/2 trial of mRNA-3927, an investigational mRNA therapy for propionic acidemia (PA). The trial showed encouraging early signs of dose-dependent pharmacology and potential clinical benefits, with no dose-limiting toxicities or study discontinuations due to drug-related treatment-emergent adverse events.

Portfolio Pulse from Happy Mohamed

May 19, 2023 | 12:23 pm

AZYO

Aziyo Biologics (NASDAQ:AZYO) announced positive data from the HEAL Study, which supports the wound-healing benefits of CanGaroo Biologic Envelope in patients receiving cardiac implantable electronic devices (CIED). The study will be presented at the Heart Rhythm Society (HRS 2023) on May 21, 2023.

Portfolio Pulse from Happy Mohamed

May 19, 2023 | 12:18 pm